Arch Biopartners Inc

February 5, 2016February 18, 2016

Respiratory Infections in CF Patients Are Focus of Orphan Drug Application in Europe

News

Arch Biopartners recently announced that it filed an application for orphan drug designation to the European Medicines Authority (EMA) for its medicine AB569, developed as a treatment for the bacterium Pseudomonas aeruginosa (P. aeruginosa) that ... Read more

November 17, 2015November 17, 2015

Arch Biopartners’ Cystic Fibrosis Therapy Given Orphan Drug Designation

Cystic Fibrosis, News

Arch Biopartners Inc., a biotechnology company focused on the development of new technologies with clinical relevance, has announced that its investigational drug AB569 has been granted Orphan Drug Designation by the U.S. Food ... Read more

September 18, 2015November 5, 2015

Arch Biopartners New Therapy Could Treat Infections With Resistant P. Aeruginosa in CF Patients

Cystic Fibrosis, News

On September 17th, 2015, Arch Biopartners Inc. announced that the drug AB569 designed to treat pulmonary infections with Pseudomonas aeruginosa (P. aeruginosa) completed successful pre-clinical in vitro and in vivo ... Read more